Across 24 safety-evaluable patients treated with Adicet Bio's prula-cel, there were no cases of cytokine release syndrome greater than Grade 2, no IEC-HS, no ICANS, and no graft-versus-host disease.

From the articleWedbush raises Adicet Bio stock price target on lupus trial data By Investing.comAlso in Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis, An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus